Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.
Jubilant Therapeutics exploits innovative discovery engine using structure based design, computational modelling and bio-informatics. Preclinical candidates have been identified for two lead programs with plans to go to Phase I in 12-18 months
1.Novel Dual inhibitors of LSD1/HDAC6 targeting cancer (AML, MDS, SCLC)
2.PAD4 inhibitors targeting auto-immune disorders (RA, Idiopathic Pulmonary Fibrosis)
3.Novel small molecule PD-L1 inhibitors
Jubilant Therapeutics exploits innovative discovery engine using structure based design, computational modelling and bio-informatics. Preclinical candidates have been identified for two lead programs with plans to go to Phase I in 12-18 months
1.Novel Dual inhibitors of LSD1/HDAC6 targeting cancer (AML, MDS, SCLC)
2.PAD4 inhibitors targeting auto-immune disorders (RA, Idiopathic Pulmonary Fibrosis)
3.Novel small molecule PD-L1 inhibitors
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Novel Dual inhibitors of LSD1/HDAC6 targeting cancer; PAD4 inhibitors targeting Autoimmune diseases
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
